Skin Melanoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SKN019 MIFTS: 71	Skin Melanoma Categories: Cancer diseases, Ear diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma ¹² ⁵⁴ ¹⁵

Cutaneous Melanoma ¹² ⁶ ¹⁵ ¹⁷ ⁷¹

Malignant Melanoma of Ear and/or External Auricular Canal ¹²

Malignant Melanoma of Skin of Trunk Except Scrotum ¹²

Malignant Melanoma of Skin of Lower Limb ¹²

Malignant Melanoma of Skin of Upper Limb ¹²

Melanoma, Cutaneous Malignant ⁴⁴

Malignant Lower Limb Melanoma ¹²

Malignant Upper Limb Melanoma ¹²

Malignant Scalp Melanoma ¹²

Malignant Trunk Melanoma ¹²

Malignant Neck Melanoma ¹²

Malignant Ear Melanoma ¹²

Malignant Lip Melanoma ¹²

Melanoma ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases Ear diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Melanoma and other malignant neoplasms of skin

Malignant melanoma of skin

Malignant neoplasm: Malignant melanoma of skin, unspecified

External Ids:

Disease Ontology ¹² DOID:8923

ICD9CM ³⁴ 172.9

MeSH ⁴⁴ C562393

NCIt ⁵⁰ C3510

SNOMED-CT ⁶⁷ 269577007

ICD10 ³² C43 C43.9

EFO ¹⁷ EFO_0000389

UMLS ⁷¹ C0025202 C0151779

Sources

Summaries for Skin Melanoma

Disease Ontology : ¹² A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and acral lentiginous melanoma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Melanoma is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Triamcinolone and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and t cells, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 603)

#	Related Disease	Score	Top Affiliating Genes
1	melanoma, cutaneous malignant 1	33.8	TP53 PTEN NRAS MITF MC1R MAP2K1
2	acral lentiginous melanoma	32.9	PTEN NRAS MC1R KIT HRAS CDKN2A
3	melanoma in congenital melanocytic nevus	32.7	NRAS MITF MC1R KIT HRAS GNAQ
4	spitzoid melanoma	32.6	NRAS HRAS GNAQ GNA11 CDKN2A BRAF
5	melanoma	32.4	TP53 PTEN NRAS MITF MC1R MAP2K1
6	skin carcinoma	31.9	TP53 PTEN NRAS MITF MC1R MAP2K1
7	mucosal melanoma	31.7	NRAS MITF KIT GNAQ GNA11 CDKN2A
8	lentigo maligna melanoma	31.7	MITF MC1R
9	neuroblastoma	31.3	TP53 PTEN NRAS MAP2K1 KIT HRAS
10	nodular malignant melanoma	31.3	TP53 NRAS MITF MC1R KIT HRAS
11	squamous cell carcinoma	31.3	TP53 PTEN MAP2K1 HRAS ERBB2 CTNNB1
12	leukemia, chronic lymphocytic	31.3	TP53 PTEN NRAS HRAS ERBB2 CDK4
13	myeloma, multiple	31.3	TP53 PTEN NRAS KIT HRAS ERBB2
14	actinic keratosis	31.2	TP53 MITF MC1R HRAS CTNNB1 CDKN2A
15	spitz nevus	31.2	TP53 HRAS CDKN2A BRAF
16	ocular melanoma	31.2	NRAS MC1R KIT GNAQ GNA11 CDKN2A
17	pancreatic cancer	31.2	TP53 PTEN MAP2K1 HRAS ERBB2 CTNNB1
18	basal cell carcinoma	31.2	TP53 PTEN MC1R KIT CTNNB1 CDKN2A
19	kaposi sarcoma	31.1	TP53 MAP2K1 CDK4 AKT1
20	endometrial cancer	31.1	TP53 PTEN NRAS KIT HRAS ERBB2
21	keratosis, seborrheic	31.1	TP53 MC1R CDKN2A
22	diffuse large b-cell lymphoma	31.1	TP53 PTEN CDKN2A CDK4 AKT1
23	lymphoma, non-hodgkin, familial	31.1	TP53 NRAS MAP2K1 BRAF AKT1
24	gastrointestinal stromal tumor	31.1	TP53 PTEN KIT ERBB2 CDKN2A BRAF
25	in situ carcinoma	31.1	TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
26	hemangioma	31.0	TP53 PTEN KIT GNAQ GNA11 CTNNB1
27	melanoma, uveal	31.0	TP53 PTEN NRAS MITF MC1R MAP2K1
28	malignant conjunctival melanoma	30.9	NRAS HRAS GNAQ GNA11
29	merkel cell carcinoma	30.9	TP53 KIT CTNNB1 CDKN2A
30	exanthem	30.9	KIT HRAS ERBB2 AKT1
31	adenocarcinoma	30.9	TP53 PTEN MAP2K1 KIT HRAS ERBB2
32	rhabdomyosarcoma	30.9	TP53 PTEN NRAS MAP2K1 KIT HRAS
33	connective tissue cancer	30.9	TP53 PTEN CDKN2A AKT1
34	gastric cancer	30.9	TP53 PTEN NRAS MAP2K1 KIT HRAS
35	neurofibromatosis, type i	30.9	TP53 PTEN NRAS MAP2K1 KIT HRAS
36	neurofibroma	30.8	TP53 PTEN MITF KIT ERBB2 CDKN2A
37	li-fraumeni syndrome	30.8	TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
38	prostate cancer	30.8	TP53 PTEN PCAT29 MAP2K1 HRAS ERBB2
39	retinitis pigmentosa	30.8	TP53 PTEN MITF KIT HRAS ERBB2
40	brain cancer	30.8	TP53 PTEN NRAS HRAS CTNNB1 BRAF
41	endometrial adenocarcinoma	30.8	TP53 PTEN ERBB2 CTNNB1 CDKN2A AKT1
42	sarcoma	30.8	TP53 NRAS KIT HRAS CTNNB1 CDK4
43	kidney cancer	30.8	TP53 PTEN CDKN2A AKT1
44	small cell carcinoma	30.8	TP53 PTEN KIT ERBB2 CDKN2A
45	ductal carcinoma in situ	30.8	TP53 PTEN ERBB2 CDKN2A AKT1
46	cervical cancer	30.8	TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
47	cowden syndrome	30.8	TP53 PTEN HRAS ERBB2 CTNNB1 AKT1
48	skin squamous cell carcinoma	30.8	TP53 HRAS ERBB2 CDKN2A BRAF
49	esophageal cancer	30.8	TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
50	liposarcoma	30.8	TP53 PTEN CTNNB1 CDKN2A CDK4

Graphical network of the top 20 diseases related to Skin Melanoma:

Sources

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:

pruritus, exanthema

GenomeRNAi Phenotypes related to Skin Melanoma according to GeneCards Suite gene sharing:

²⁶ (show all 16)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.21	HRAS
2	Decreased viability	GR00055-A-2	10.21	HRAS
3	Decreased viability	GR00107-A-1	10.21	MAP2K1
4	Decreased viability	GR00221-A-1	10.21	AKT1 CDKN2A HRAS KIT NRAS
5	Decreased viability	GR00221-A-2	10.21	AKT1 HRAS
6	Decreased viability	GR00221-A-3	10.21	AKT1 CDKN2A HRAS NRAS ERBB2 MAP2K1
7	Decreased viability	GR00221-A-4	10.21	AKT1 CDKN2A ERBB2
8	Decreased viability	GR00249-S	10.21	AKT1
9	Decreased viability	GR00301-A	10.21	KIT
10	Decreased substrate adherent cell growth	GR00193-A-1	9.76	KIT
11	Decreased substrate adherent cell growth	GR00193-A-2	9.76	CDK4 KIT
12	Decreased substrate adherent cell growth	GR00193-A-3	9.76	BRAF CDK4
13	Decreased substrate adherent cell growth	GR00193-A-4	9.76	BRAF CDK4 KIT
14	Decreased cell migration	GR00055-A-1	9.56	AKT1 CDK4
15	Decreased cell migration	GR00055-A-3	9.56	BRAF HRAS
16	Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading	GR00210-A	8.32	CTNNB1

MGI Mouse Phenotypes related to Skin Melanoma:

⁴⁶ (show all 27)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.54	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
2	growth/size/body region	MP:0005378	10.52	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
3	cardiovascular system	MP:0005385	10.5	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
4	endocrine/exocrine gland	MP:0005379	10.5	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
5	homeostasis/metabolism	MP:0005376	10.5	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
6	integument	MP:0010771	10.48	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
7	cellular	MP:0005384	10.47	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
8	craniofacial	MP:0005382	10.46	BRAF CDK4 CTNNB1 ERBB2 FBN1 GNA11
9	embryo	MP:0005380	10.42	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
10	hematopoietic system	MP:0005397	10.42	AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
11	mortality/aging	MP:0010768	10.41	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
12	immune system	MP:0005387	10.4	AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
13	digestive/alimentary	MP:0005381	10.35	BRAF CDK4 CDKN2A CTNNB1 ERBB2 HRAS
14	nervous system	MP:0003631	10.33	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
15	limbs/digits/tail	MP:0005371	10.31	BRAF CTNNB1 ERBB2 FBN1 GNA11 GNAQ
16	muscle	MP:0005369	10.31	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
17	neoplasm	MP:0002006	10.29	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
18	liver/biliary system	MP:0005370	10.26	AKT1 BRAF CDK4 CDKN2A CTNNB1 GNA11
19	normal	MP:0002873	10.25	AKT1 BRAF CDK4 CTNNB1 ERBB2 GNA11
20	hearing/vestibular/ear	MP:0005377	10.24	BRAF CTNNB1 GNA11 GNAQ KIT MAP2K1
21	pigmentation	MP:0001186	10.18	BRAF CDK4 CDKN2A CTNNB1 FBN1 GNA11
22	no phenotypic analysis	MP:0003012	10.09	CDKN2A CTNNB1 FBN1 HRAS KIT MC1R
23	renal/urinary system	MP:0005367	10.06	BRAF CDK4 CTNNB1 FBN1 GNA11 GNAQ
24	reproductive system	MP:0005389	10.03	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
25	respiratory system	MP:0005388	9.93	AKT1 BRAF CDKN2A CTNNB1 ERBB2 FBN1
26	skeleton	MP:0005390	9.86	AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
27	vision/eye	MP:0005391	9.32	BRAF CDK4 CDKN2A CTNNB1 KIT MAP2K1

Sources

Drugs & Therapeutics for Skin Melanoma

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 530)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Vindesine

Approved, Investigational

Phase 4

53643-48-4, 59917-39-4

40839

Etanercept

Approved, Investigational

Phase 4

185243-69-0

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

445643 439492 6473866

Dopamine

Approved

Phase 4

51-61-6, 62-31-7

681

Pasireotide

Approved

Phase 4

396091-73-9

9941444

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Somatostatin

Approved, Investigational

Phase 4

51110-01-1, 38916-34-6

53481605

Cabergoline

Approved

Phase 4

81409-90-7

54746

Triamcinolone hexacetonide

Phase 4

triamcinolone acetonide

Phase 4

Triamcinolone diacetate

Phase 4

Calcineurin Inhibitors

Phase 4

Hemostatics

Phase 4

Cyclosporins

Phase 4

Fibrin Tissue Adhesive

Phase 4

Coagulants

Phase 4

Neurotransmitter Agents

Phase 4

Dopamine Agents

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Dopamine agonists

Phase 4

Antiparkinson Agents

Phase 4

Treosulfan

Approved, Investigational

Phase 3

299-75-2

9296

Timolol

Approved

Phase 3

26839-75-8

33624 5478

Ranibizumab

Approved

Phase 3

347396-82-1

459903

tannic acid

Approved

Phase 2, Phase 3

1401-55-4

Benzocaine

Approved, Investigational

Phase 2, Phase 3

1994-09-7, 94-09-7

2337

Aminolevulinic acid

Approved

Phase 3

106-60-5

137

Peginterferon alfa-2a

Approved, Investigational

Phase 3

198153-51-4

5360545

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Imiquimod

Approved, Investigational

Phase 3

99011-02-6

57469

leucovorin

Approved

Phase 3

58-05-9

6006

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

BCG vaccine

Approved, Investigational

Phase 3

Peginterferon alfa-2b

Approved

Phase 2, Phase 3

215647-85-1, 99210-65-8

Xylometazoline

Approved, Investigational

Phase 3

526-36-3

5709

Tyrosine

Approved, Investigational, Nutraceutical

Phase 3

60-18-4

6057

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 3

1406-16-2

Vitamin D3

Approved, Nutraceutical

Phase 3

67-97-0

6221 5280795

Imidacloprid

Vet_approved

Phase 3

105827-78-9

86418

Fotemustine

Investigational

Phase 3

92118-27-9

Oblimersen

Experimental, Investigational

Phase 2, Phase 3

190977-41-4

Detox adjuvant

Phase 3

polysaccharide-K

Phase 3

Photosensitizing Agents

Phase 3

Methyl 5-aminolevulinate

Phase 3

Olive

Phase 3

Pharmaceutical Solutions

Phase 2, Phase 3

Central Nervous System Stimulants

Phase 3

Interventional clinical trials:

(show top 50) (show all 2398)

#	Name	Status	NCT ID	Phase	Drugs
1	Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies	Unknown status	NCT02626065	Phase 4	Nivolumab
2	A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma	Unknown status	NCT00540930	Phase 4	Ranibizumab
3	Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma	Unknown status	NCT00226473	Phase 4	Cisplatin, Vindesine, Dacarbazine (drugs)
4	Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy	Unknown status	NCT02379000	Phase 4	Triamcinolone Acetonide
5	Can We Miss Pigmented Lesions in Psoriasis Patients?	Completed	NCT01053819	Phase 4	etanercept
6	Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream	Completed	NCT02685592	Phase 4	5-aminolevulinic acid nanoemulsion
7	A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen	Completed	NCT00129961	Phase 4	sirolimus;cyclosporine or tacrolimus
8	An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.	Completed	NCT01898585	Phase 4	Zelboraf
9	Neoadjuvant GM-CSF Treatment and Modulation of Immune Cell Profile of the SLN in Melanoma	Completed	NCT02451488	Phase 4	GM-CSF
10	Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial.	Completed	NCT00324272	Phase 4	Fibrin Sealant (Tisseel) used in the Experimental Arm.
11	Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial	Recruiting	NCT03673332	Phase 4	immune-checkpoint inhibitors therapies
12	A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)	Recruiting	NCT03715205	Phase 4	Pembrolizumab
13	Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study	Recruiting	NCT03340506	Phase 4	dabrafenib;trametinib
14	Phase IV Ipilimumab in Melanoma: A National, Multicenter, Interventional Study in Patients With Unresectable or Metastatic Melanoma	Active, not recruiting	NCT02068196	Phase 4	Ipilimumab
15	An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment	Active, not recruiting	NCT01794793	Phase 4	Pasireotide;Cabergoline;Pasireotide
16	Influenza Vaccine Responses in the Setting of Melanoma Treatment	Enrolling by invitation	NCT03315975	Phase 4
17	An Exploratory Prospective, Open-label, Unicentric Study With Cross-over Design, Comparing Lymphoseek® vs. Albumin Nanocolloid for Image- Guided Sentinel Lymph Node Mapping in Head and Neck, Melanoma and Breast Cancer.	Not yet recruiting	NCT04261179	Phase 4	Lymphoseek;Nanocoll
18	Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1)	Not yet recruiting	NCT03313544	Phase 4	Nivolumab
19	Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma	Terminated	NCT01856023	Phase 4	High Dose Interleukin-2;Ipilimumab
20	A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma	Terminated	NCT01683188	Phase 4	vemurafenib + HD IL-2
21	Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer	Withdrawn	NCT02000739	Phase 4
22	Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients	Unknown status	NCT01729663	Phase 2, Phase 3	interferon alpha 2b
23	Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients	Unknown status	NCT01861938	Phase 2, Phase 3
24	Comparison of M-Vax Plus Low Dose Interleukin-2 Versus Placebo Vaccine Plus Low Dose Interleukin-2 in Patients With Stage IV Melanoma	Unknown status	NCT00477906	Phase 3
25	Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma.	Unknown status	NCT00811200	Phase 2, Phase 3	ranibizumab;triamcinolone acetonide
26	Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.	Unknown status	NCT01502696	Phase 3
27	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation	Unknown status	NCT00005052	Phase 3
28	Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma	Unknown status	NCT00052130	Phase 3
29	A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma	Unknown status	NCT00052156	Phase 3
30	A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients	Unknown status	NCT02938299	Phase 3	L19IL2 + L19TNF
31	A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis	Unknown status	NCT00039234	Phase 3	histamine dihydrochloride
32	PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial	Unknown status	NCT00006249	Phase 3
33	PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA	Unknown status	NCT00002767	Phase 3
34	POST-OPERATIVE ADJUVANT INTERFERON-ALFA-2B (INTRON-A) TREATMENT AFTER RESECTION OF THICK PRIMARY MELANOMA AND/OR REGIONAL LYMPHNODE METASTASES 'INTERMEDIATE-HIGH DOSE' VS INTERMEDIATE-LOW DOSE' IFN-ALFA VS OBSERVATION: A 3-ARM MULTICENTER RANDOMIZED PHASE III TRIAL	Unknown status	NCT00002763	Phase 3
35	Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma	Unknown status	NCT00779714	Phase 3	DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
36	Collaborative Ocular Melanoma Study (COMS)	Unknown status	NCT00000124	Phase 3
37	Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy	Unknown status	NCT00226408	Phase 3	Interferon-alpha-2b
38	Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma	Unknown status	NCT02843386	Phase 3	Adjuvant chemotherapy by Fotemustin
39	A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis	Unknown status	NCT02460068	Phase 3	Fotemustine;Fotemustine and Ipilimumab;Ipilimumab and nivolumab
40	A Multicenter, Randomized, Controlled, Phase III Trial Comparing High-Dose IFN-a2b With Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma	Unknown status	NCT03435302	Phase 3	Temozolomide Plus Cisplatin;High-Dose IFN-a2b
41	Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel	Unknown status	NCT01272609	Phase 3	Timolol + LCP
42	Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts	Unknown status	NCT00002455	Phase 3
43	Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma	Completed	NCT00003647	Phase 3	allovectin-7;allovectin-7/dacarbazine;dacarbazine
44	TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision	Completed	NCT00200577	Phase 3	TIL + IL2
45	A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma	Completed	NCT01227889	Phase 3	GSK2118436;Dacarbazine (DTIC)
46	A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma	Completed	NCT00094653	Phase 3	MDX-010 (anti-CTLA4) monoclonal antibody
47	A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping	Completed	NCT00671918	Phase 3	Lymphoseek
48	A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma	Completed	NCT01689519	Phase 3	Placebo;Vemurafenib;Cobimetinib
49	The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma	Completed	NCT01763164	Phase 3	MEK162;Dacarbazine
50	A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver	Completed	NCT00324727	Phase 3	melphalan;regional chemotherapy;systemic chemotherapy

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵¹ :

Aldesleukin

Carmustine

dabrafenib

Dacarbazine

docetaxel

hydroxyurea

Interferon Alfa-2a

Interferon Alfa-2b

INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED

interferon alfacon-1

Interferon gamma-1b

Interferons

Lomustine

peginterferon alfa-2a

peginterferon alfa-2b

pembrolizumab

Procarbazine

Procarbazine Hydrochloride

Recombinant interferon beta-1a

Recombinant interferon beta-1b

temozolomide

trametinib

Vemurafenib

Cochrane evidence based reviews: melanoma, cutaneous malignant

Sources

Genetic Tests for Skin Melanoma

Sources

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

⁴⁰

Skin, Lymph Node, T Cells, Liver, Breast, Brain, Lung

Sources

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 7983)

#	Title	Authors	PMID	Year
1	Codon-specific translation reprogramming promotes resistance to targeted therapy. ⁶	Rapino F...Close P	29925953	2018
2	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. ⁶	Mass E...Geissmann F	28854169	2017
3	eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. ⁶	Boussemart L...Vagner S	25079330	2014
4	Copper is required for oncogenic BRAF signalling and tumorigenesis. ⁶	Brady DC...Counter CM	24717435	2014
5	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. ⁶	Sun C...Bernards R	24670642	2014
6	Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. ⁶	Gala MK...Chung DC	24512911	2014
7	A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. ⁶	Kaplon J...Peeper DS	23685455	2013
8	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. ⁶	Das Thakur M...Stuart DD	23302800	2013
9	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. ⁶	Prahallad A...Bernards R	22281684	2012
10	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). ⁶	Poulikakos PI...Solit DB	22113612	2011
11	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. ⁶	Johannessen CM...Garraway LA	21107320	2010
12	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. ⁶	Nazarian R...Lo RS	21107323	2010
13	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. ⁶	Bollag G...Nolop K	20823850	2010
14	Inhibition of mutated, activated BRAF in metastatic melanoma. ⁶	Flaherty KT...Chapman PB	20818844	2010
15	New common variants affecting susceptibility to basal cell carcinoma. ⁶	Stacey SN...Stefansson K	19578363	2009
16	SLC45A2: a novel malignant melanoma-associated gene. ⁶	Fernandez LP...Ribas G	18563784	2008
17	Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. ⁶	Guedj M...MelanCohort Investigators	18683857	2008
18	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. ⁶	Pfister S...Lichter P	18398503	2008
19	A genomewide association study of skin pigmentation in a South Asian population. ⁶	Stokowski RP...Cox DR	17999355	2007
20	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. ⁶	Lupi C...Basolo F	17785355	2007
21	BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. ⁶	Durante C...Russo D	17488796	2007
22	BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. ⁶	Liu D...Xing M	17374713	2007
23	Distribution of the F374 allele of the SLC45A2 (MATP) gene and founder-haplotype analysis. ⁶	Yuasa I...Henke J	17044855	2006
24	Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. ⁶	Jo YS...Shong M	16772349	2006
25	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. ⁶	Xing M...Ladenson PW	16174717	2005
26	High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. ⁶	Vasko V...Xing M	15998781	2005
27	BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. ⁶	Lubomierski N...Raedle J	16015629	2005
28	High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. ⁶	Hishinuma A...Ieiri T	16187918	2005
29	Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. ⁶	Porra V...Rousset B	15687339	2005
30	Mutations of BRAF and RAS are rare events in germ cell tumours. ⁶	Sommerer F...Tannapfel A	15386408	2005
31	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. ⁶	Domingo E...Schwartz S	15342696	2004
32	Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. ⁶	Kumagai A...Yamashita S	15356022	2004
33	Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. ⁶	Xing M...Ladenson PW	15181070	2004
34	BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. ⁶	Puxeddu E...Santeusanio F	15126572	2004
35	BRAF T1796A transversion mutation in various thyroid neoplasms. ⁶	Xing M...Sidransky D	15001635	2004
36	Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. ⁶	Kim IJ...Park JG	14513361	2003
37	BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. ⁶	Nikiforova MN...Nikiforov YE	14602780	2003
38	Exclusion of BRAFV599E as a melanoma susceptibility mutation. ⁶	Meyer P...Garbe C	12794760	2003
39	BRAF mutations in metastatic melanoma: a possible association with clinical outcome. ⁶	Kumar R...Hemminki K	12960123	2003
40	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. ⁶	Kimura ET...Fagin JA	12670889	2003
41	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. ⁶	Singer G...Shih IeM	12644542	2003
42	Absence of exon 15 BRAF germline mutations in familial melanoma. ⁶	Lang J...MacKie R	12619120	2003
43	High frequency of BRAF mutations in nevi. ⁶	Pollock PM...Meltzer PS	12447372	2003
44	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. ⁶	Rajagopalan H...Velculescu VE	12198537	2002
45	Mutations of the BRAF gene in human cancer. ⁶	Davies H...Futreal PA	12068308	2002
46	Identification of PTEN mutations in metastatic melanoma specimens. ⁶	Celebi JT...Peacocke M	10978354	2000
47	Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. ⁵⁴ ⁶¹	Soto Martinez JL...Lopez-Nevot MA	15960923	2005
48	The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. ⁶¹ ⁵⁴	Dome B...Timar J	11268486	2000
49	Differential expression of nm23 H-1 protein in conjunctival melanoma and potential precursor lesions. ⁵⁴ ⁶¹	Seregard S...Spangberg B	10620396	1999
50	[Prognosis and invasion marker expression of cutaneous melanoma. Metastasis-associated genes (nm23, CD44v3, MMP2]. ⁶¹ ⁵⁴	Dome B...Timar J	10064977	1999

Sources

Genes for Skin Melanoma

Genes related to Skin Melanoma (10 elite genes):

(show top 50) (show all 161)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	440.81	Pathogenic ⁶ Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	440.3	Pathogenic ⁶ Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	439.09	Pathogenic ⁶ Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	PTEN	Phosphatase And Tensin Homolog	Protein Coding	438.97	Pathogenic ⁶ Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	10978354
5	GNA11	G Protein Subunit Alpha 11	Protein Coding	432.99	Pathogenic ⁶ Likely pathogenic ⁶ DISEASES inferred ¹⁵
6	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	432.83	Pathogenic ⁶ Likely pathogenic ⁶ DISEASES inferred ¹⁵
7	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	431.85	Pathogenic ⁶ Likely pathogenic ⁶ DISEASES inferred ¹⁵
8	CTNNB1	Catenin Beta 1	Protein Coding	431.51	Pathogenic ⁶ Likely pathogenic ⁶ DISEASES inferred ¹⁵
9	GNAQ	G Protein Subunit Alpha Q	Protein Coding	408.05	Pathogenic ⁶ DISEASES inferred ¹⁵
10	FBN1	Fibrillin 1	Protein Coding	400	Pathogenic ⁶
11	LINC00937	Long Intergenic Non-Protein Coding RNA 937	RNA Gene	155.18	Experimental evidence: Interaction ³⁸ DISEASES inferred ¹⁵	29522273
12	DRAIC	Downregulated RNA In Cancer, Inhibitor Of Cell Invasion And Migration	RNA Gene	150	Experimental evidence ³⁸	25700553
13	PCAT29	Prostate Cancer Associated Transcript 29	RNA Gene	150	Experimental evidence ³⁸	25700553
14	MITF	Melanocyte Inducing Transcription Factor	Protein Coding	39.8	Risk factor ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	TP53	Tumor Protein P53	Protein Coding	39.65	Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	37.7	Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	33.34	Likely pathogenic ⁶ DISEASES inferred ¹⁵
18	MC1R	Melanocortin 1 Receptor	Protein Coding	33.02	Risk factor ⁶ DISEASES inferred ¹⁵
19	CDK4	Cyclin Dependent Kinase 4	Protein Coding	32.35	Likely pathogenic ⁶ DISEASES inferred ¹⁵
20	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	32	Likely pathogenic ⁶ DISEASES inferred ¹⁵
21	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	31.75	Likely pathogenic ⁶ DISEASES inferred ¹⁵
22	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	31.48	Likely pathogenic ⁶ DISEASES inferred ¹⁵
23	ARAF	A-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	31.27	Likely pathogenic ⁶ DISEASES inferred ¹⁵
24	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	31.1	Likely pathogenic ⁶ DISEASES inferred ¹⁵
25	SLC45A2	Solute Carrier Family 45 Member 2	Protein Coding	30.94	Protective ⁶ DISEASES inferred ¹⁵	17044855 17999355 19578363 (more) 18683857 18563784
26	STK19	Serine/Threonine Kinase 19	Protein Coding	30.9	Likely pathogenic ⁶ DISEASES inferred ¹⁵
27	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	30.88	Likely pathogenic ⁶ DISEASES inferred ¹⁵
28	PPP6C	Protein Phosphatase 6 Catalytic Subunit	Protein Coding	30.83	Likely pathogenic ⁶ DISEASES inferred ¹⁵
29	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	30.82	Likely pathogenic ⁶ DISEASES inferred ¹⁵
30	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	30.56	Likely pathogenic ⁶ DISEASES inferred ¹⁵
31	STK11	Serine/Threonine Kinase 11	Protein Coding	30.47	Likely pathogenic ⁶ DISEASES inferred ¹⁵
32	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	30.43	Likely pathogenic ⁶ DISEASES inferred ¹⁵
33	MAP2K2	Mitogen-Activated Protein Kinase Kinase 2	Protein Coding	30.33	Likely pathogenic ⁶ DISEASES inferred ¹⁵
34	B2M	Beta-2-Microglobulin	Protein Coding	30.28	Likely pathogenic ⁶ DISEASES inferred ¹⁵
35	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	30.28	Likely pathogenic ⁶ DISEASES inferred ¹⁵
36	ERBB4	Erb-B2 Receptor Tyrosine Kinase 4	Protein Coding	30.22	Likely pathogenic ⁶ DISEASES inferred ¹⁵
37	SF3B1	Splicing Factor 3b Subunit 1	Protein Coding	30.21	Likely pathogenic ⁶ DISEASES inferred ¹⁵
38	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	29.95	Likely pathogenic ⁶ DISEASES inferred ¹⁵
39	PIK3R1	Phosphoinositide-3-Kinase Regulatory Subunit 1	Protein Coding	29.81	Likely pathogenic ⁶ DISEASES inferred ¹⁵
40	GNAS	GNAS Complex Locus	Protein Coding	29.59	Likely pathogenic ⁶ DISEASES inferred ¹⁵
41	RAC1	Rac Family Small GTPase 1	Protein Coding	29.35	Likely pathogenic ⁶ DISEASES inferred ¹⁵
42	CREBBP	CREB Binding Protein	Protein Coding	29	Likely pathogenic ⁶ DISEASES inferred ¹⁵
43	CNOT9	CCR4-NOT Transcription Complex Subunit 9	Protein Coding	28.87	Likely pathogenic ⁶ DISEASES inferred ¹⁵
44	KNSTRN	Kinetochore Localized Astrin (SPAG5) Binding Protein	Protein Coding	28.78	Likely pathogenic ⁶ DISEASES inferred ¹⁵
45	BCL2L12	BCL2 Like 12	Protein Coding	28.45	Likely pathogenic ⁶ DISEASES inferred ¹⁵
46	CRNKL1	Crooked Neck Pre-MRNA Splicing Factor 1	Protein Coding	25	Likely pathogenic ⁶
47	SF3B2	Splicing Factor 3b Subunit 2	Protein Coding	25	Likely pathogenic ⁶
48	TYR	Tyrosinase	Protein Coding	20.64	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	11952287
49	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	17.21	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15960923
50	PMEL	Premelanosome Protein	Protein Coding	14.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Skin Melanoma

ClinVar genetic disease variations for Skin Melanoma:

⁶ (show top 50) (show all 455)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	SLC45A2	NM_016180.5(SLC45A2):c.1122= (p.Leu374=)	SNV	protective	4505	rs16891982	5:33951693-33951693	5:33951588-33951588
2	PTEN	NM_000314.7(PTEN):c.649G>A (p.Val217Ile)	SNV	Pathogenic	7838	rs121909234	10:89717624-89717624	10:87957867-87957867
3	MAP2K1	NM_002755.3(MAP2K1):c.607G>A (p.Glu203Lys)	SNV	Pathogenic	375982	rs1057519733	15:66774131-66774131	15:66481793-66481793
4	NRAS	NM_002524.5(NRAS):c.38G>C (p.Gly13Ala)	SNV	Pathogenic	375877	rs121434596	1:115258744-115258744	1:114716123-114716123
5	BRAF	NM_004333.6(BRAF):c.1798_1799delinsAA (p.Val600Lys)	Indel	Pathogenic	375941	rs121913227	7:140453136-140453137	7:140753336-140753337
6	BRAF	NM_004333.6(BRAF):c.1799_1800delinsAT (p.Val600Asp)	Indel	Pathogenic	375939	rs121913377	7:140453135-140453136	7:140753335-140753336
7	BRAF	NM_001374258.1(BRAF):c.1918G>A (p.Val640Met)	SNV	Pathogenic	44815	rs121913378	7:140453137-140453137	7:140753337-140753337
8	BRAF	NM_004333.6(BRAF):c.1798_1799delinsAG (p.Val600Arg)	Indel	Pathogenic	375940	rs121913227	7:140453136-140453137	7:140753336-140753337
9	NRAS	NM_002524.5(NRAS):c.35G>A (p.Gly12Asp)	SNV	Pathogenic	39648	rs121913237	1:115258747-115258747	1:114716126-114716126
10	NRAS	NM_002524.5(NRAS):c.37G>T (p.Gly13Cys)	SNV	Pathogenic	40471	rs121434595	1:115258745-115258745	1:114716124-114716124
11	PTEN	NM_000314.8(PTEN):c.633C>A	SNV	Pathogenic	7836	rs121909232	10:89712015-89712015	10:87952258-87952258
12	NRAS	NM_002524.5(NRAS):c.35G>T (p.Gly12Val)	SNV	Pathogenic	40470	rs121913237	1:115258747-115258747	1:114716126-114716126
13	KIT	NM_000222.2(KIT):c.1676T>A (p.Val559Asp)	SNV	Pathogenic	13856	rs121913517	4:55593610-55593610	4:54727444-54727444
14	KIT	NM_000222.2(KIT):c.1965T>A (p.Asn655Lys)	SNV	Pathogenic	375923	rs1057519708	4:55594262-55594262	4:54728096-54728096
15	NRAS	NM_002524.5(NRAS):c.182_183delinsTG (p.Gln61Leu)	Indel	Pathogenic	375872	rs1057519695	1:115256528-115256529	1:114713907-114713908
16	BRAF	NM_004333.6(BRAF):c.1789_1790delinsTC (p.Leu597Ser)	Indel	Pathogenic	375942	rs121913368	7:140453145-140453146	7:140753345-140753346
17	MAP2K1	NM_002755.4(MAP2K1):c.1144A>C (p.Asn382His)	SNV	Pathogenic	375984	rs1057519735	15:66782915-66782915	15:66490577-66490577
18	MAP2K1	NM_002755.3(MAP2K1):c.157T>C (p.Phe53Leu)	SNV	Pathogenic	375977	rs1057519728	15:66727441-66727441	15:66435103-66435103
19	MAP2K1	NM_002755.3(MAP2K1):c.332T>G (p.Ile111Ser)	SNV	Pathogenic	375979	rs1057519730	15:66729124-66729124	15:66436786-66436786
20	MAP2K1	NM_002755.3(MAP2K1):c.790C>T (p.Pro264Ser)	SNV	Pathogenic	375983	rs1057519734	15:66777424-66777424	15:66485086-66485086
21	BRAF	NM_004333.6(BRAF):c.1782T>A (p.Asp594Glu)	SNV	Pathogenic	375945	rs121913337	7:140453153-140453153	7:140753353-140753353
22	NRAS	NM_002524.5(NRAS):c.182_183delinsGG (p.Gln61Arg)	Indel	Pathogenic	375873	rs1057519695	1:115256528-115256529	1:114713907-114713908
23	BRAF	NM_004333.6(BRAF):c.1779_1780delinsGA (p.Asp594Asn)	Indel	Pathogenic	375948	rs1057519718	7:140453155-140453156	7:140753355-140753356
24	NRAS	NM_002524.5(NRAS):c.181C>G (p.Gln61Glu)	SNV	Pathogenic	375875	rs121913254	1:115256530-115256530	1:114713909-114713909
25	KIT	NM_000222.2(KIT):c.1676T>G (p.Val559Gly)	SNV	Pathogenic	375912	rs121913517	4:55593610-55593610	4:54727444-54727444
26	KIT	NM_000222.2(KIT):c.1679T>A (p.Val560Asp)	SNV	Pathogenic	375914	rs121913521	4:55593613-55593613	4:54727447-54727447
27	KIT	NM_000222.2(KIT):c.1679T>G (p.Val560Gly)	SNV	Pathogenic	375916	rs121913521	4:55593613-55593613	4:54727447-54727447
28	KIT	NM_000222.2(KIT):c.2485G>C (p.Ala829Pro)	SNV	Pathogenic	375933	rs1057519713	4:55602664-55602664	4:54736498-54736498
29	CTNNB1	NM_001904.4(CTNNB1):c.134C>A (p.Ser45Tyr)	SNV	Pathogenic	375895	rs121913409	3:41266137-41266137	3:41224646-41224646
30	KIT	NM_000222.2(KIT):c.1650A>T (p.Lys550Asn)	SNV	Pathogenic	375906	rs1057519703	4:55593584-55593584	4:54727418-54727418
31	KIT	NM_000222.2(KIT):c.1669T>A (p.Trp557Arg)	SNV	Pathogenic	375908	rs121913235	4:55593603-55593603	4:54727437-54727437
32	NRAS	NM_002524.5(NRAS):c.38G>T (p.Gly13Val)	SNV	Pathogenic	375876	rs121434596	1:115258744-115258744	1:114716123-114716123
33	NRAS	NM_002524.5(NRAS):c.37G>C (p.Gly13Arg)	SNV	Pathogenic	13899	rs121434595	1:115258745-115258745	1:114716124-114716124
34	GNAQ	NM_002072.5(GNAQ):c.626A>C (p.Gln209Pro)	SNV	Pathogenic	375957	rs121913492	9:80409488-80409488	9:77794572-77794572
35	GNA11	NM_002067.5(GNA11):c.626A>T (p.Gln209Leu)	SNV	Pathogenic	376002	rs1057519742	19:3118942-3118942	19:3118944-3118944
36	GNA11	NM_002067.5(GNA11):c.626A>C (p.Gln209Pro)	SNV	Pathogenic	376001	rs1057519742	19:3118942-3118942	19:3118944-3118944
37	BRAF	NM_001374258.1(BRAF):c.1909C>G (p.Leu637Val)	SNV	Pathogenic	13969	rs121913369	7:140453146-140453146	7:140753346-140753346
38	KIT	NM_000222.2(KIT):c.1727T>C (p.Leu576Pro)	SNV	Pathogenic	375919	rs121913513	4:55593661-55593661	4:54727495-54727495
39	BRAF	NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly)	SNV	Pathogenic	13972	rs121913338	7:140453154-140453154	7:140753354-140753354
40	GNAQ	NM_002072.5(GNAQ):c.626A>T (p.Gln209Leu)	SNV	Pathogenic	375955	rs121913492	9:80409488-80409488	9:77794572-77794572
41	KIT	NM_000222.2(KIT):c.2458G>C (p.Asp820His)	SNV	Pathogenic	375927	rs1057519710	4:55599332-55599332	4:54733166-54733166
42	KIT	NM_000222.3(KIT):c.2466T>G	SNV	Pathogenic	375932	rs121913514	4:55599340-55599340	4:54733174-54733174
43	KIT	NM_000222.2(KIT):c.1965T>G (p.Asn655Lys)	SNV	Pathogenic	375924	rs1057519708	4:55594262-55594262	4:54728096-54728096
44	BRAF	NM_004333.6(BRAF):c.1782T>G (p.Asp594Glu)	SNV	Pathogenic	375944	rs121913337	7:140453153-140453153	7:140753353-140753353
45	KIT	NM_000222.2(KIT):c.1510T>C (p.Phe504Leu)	SNV	Pathogenic	375904	rs1057519702	4:55592186-55592186	4:54726020-54726020
46	KIT	NM_000222.2(KIT):c.1961T>C (p.Val654Ala)	SNV	Pathogenic	375921	rs121913523	4:55594258-55594258	4:54728092-54728092
47	KIT	NM_000222.3(KIT):c.2446G>C	SNV	Pathogenic	13863	rs121913506	4:55599320-55599320	4:54733154-54733154
48	NRAS	NM_002524.5(NRAS):c.38G>A (p.Gly13Asp)	SNV	Pathogenic	13901	rs121434596	1:115258744-115258744	1:114716123-114716123
49	NRAS	NM_002524.5(NRAS):c.34G>A (p.Gly12Ser)	SNV	Pathogenic	177778	rs121913250	1:115258748-115258748	1:114716127-114716127
50	KIT	NM_000222.2(KIT):c.1679T>C (p.Val560Ala)	SNV	Pathogenic	375915	rs121913521	4:55593613-55593613	4:54727447-54727447

Cosmic variations for Skin Melanoma:

⁹ (show top 50) (show all 4660)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM95964482	ZNF451	skin,neck,malignant melanoma,NS	c.2114T>G	p.I705S	6:57148199-57148199	15
2	COSM96588509	ZNF451	skin,neck,malignant melanoma,NS	c.2114T>G	p.I705S	6:57148199-57148199	15
3	COSM119021797	ZNF451	skin,neck,malignant melanoma,NS	c.2114T>G	p.I705S	6:57148199-57148199	15
4	COSM84509782	ZNF276	skin,scalp,malignant melanoma,NS	c.*1273G>A	p.?	16:89739519-89739519	15
5	COSM143038077	YAP1	skin,neck,malignant melanoma,NS	c.1303C>T	p.Q435*	11:102229716-102229716	15
6	COSM128448849	YAP1	skin,neck,malignant melanoma,NS	c.1129C>T	p.Q377*	11:102229716-102229716	15
7	COSM145025271	YAP1	skin,neck,malignant melanoma,NS	c.1141C>T	p.Q381*	11:102229716-102229716	15
8	COSM127995004	YAP1	skin,neck,malignant melanoma,NS	c.1243C>T	p.Q415*	11:102229716-102229716	15
9	COSM133269851	YAP1	skin,neck,malignant melanoma,NS	c.1255C>T	p.Q419*	11:102229716-102229716	15
10	COSM126969981	YAP1	skin,neck,malignant melanoma,NS	c.757C>T	p.Q253*	11:102229716-102229716	15
11	COSM90944416	YAP1	skin,neck,malignant melanoma,NS	c.1189C>T	p.Q397*	11:102229716-102229716	15
12	COSM85233895	YAP1	skin,neck,malignant melanoma,NS	c.1291C>T	p.Q431*	11:102229716-102229716	15
13	COSM105837553	XRCC6	skin,scalp,malignant melanoma,NS	c.88C>T	p.R30*	22:41636155-41636155	15
14	COSM97229917	XRCC6	skin,scalp,malignant melanoma,NS	c.1054C>T	p.P352S	22:41650816-41650816	15
15	COSM105840182	XRCC6	skin,scalp,malignant melanoma,NS	c.1272-1G>T	p.?	22:41658251-41658251	15
16	COSM103711614	XRCC6	skin,scalp,malignant melanoma,NS	c.1299-1G>T	p.?	22:41658251-41658251	15
17	COSM95163322	XRCC6	skin,scalp,malignant melanoma,NS	c.238C>T	p.R80*	22:41636155-41636155	15
18	COSM95165917	XRCC6	skin,scalp,malignant melanoma,NS	c.1054C>T	p.P352S	22:41650816-41650816	15
19	COSM108016980	XRCC6	skin,scalp,malignant melanoma,NS	c.904C>T	p.P302S	22:41650816-41650816	15
20	COSM103707744	XRCC6	skin,scalp,malignant melanoma,NS	c.196-81C>T	p.?	22:41636155-41636155	15
21	COSM103710325	XRCC6	skin,scalp,malignant melanoma,NS	c.931C>T	p.P311S	22:41650816-41650816	15
22	COSM97227877	XRCC6	skin,scalp,malignant melanoma,NS	c.238C>T	p.R80*	22:41636155-41636155	15
23	COSM108015015	XRCC6	skin,scalp,malignant melanoma,NS	c.88C>T	p.R30*	22:41636155-41636155	15
24	COSM95166966	XRCC6	skin,scalp,malignant melanoma,NS	c.1422-1G>T	p.?	22:41658251-41658251	15
25	COSM106337870	XRCC6	skin,scalp,malignant melanoma,NS	c.1422-1G>T	p.?	22:41658251-41658251	15
26	COSM108018036	XRCC6	skin,scalp,malignant melanoma,NS	c.1272-1G>T	p.?	22:41658251-41658251	15
27	COSM97231271	XRCC6	skin,scalp,malignant melanoma,NS	c.1422-1G>T	p.?	22:41658251-41658251	15
28	COSM106334939	XRCC6	skin,scalp,malignant melanoma,NS	c.238C>T	p.R80*	22:41636155-41636155	15
29	COSM106336809	XRCC6	skin,scalp,malignant melanoma,NS	c.1054C>T	p.P352S	22:41650816-41650816	15
30	COSM105839222	XRCC6	skin,scalp,malignant melanoma,NS	c.904C>T	p.P302S	22:41650816-41650816	15
31	COSM111540596	WT1	skin,scalp,malignant melanoma,NS	c.742G>A	p.D248N	11:32428524-32428524	15
32	COSM111525675	WT1	skin,neck,malignant melanoma,NS	c.1322G>A	p.R441Q	11:32392031-32392031	15
33	COSM113471589	WT1	skin,neck,malignant melanoma,NS	c.1373G>A	p.R458Q	11:32392031-32392031	15
34	COSM100766084	WT1	skin,scalp,malignant melanoma,NS	c.847G>A	p.E283K	11:32389120-32389120	15
35	COSM148571624	WT1	skin,scalp,malignant melanoma,NS	c.1024G>A	p.D342N	11:32400022-32400022	15
36	COSM91384800	WT1	skin,scalp,malignant melanoma,NS	c.732C>T	p.F244=	11:32428534-32428534	15
37	COSM147420112	WT1	skin,scalp,malignant melanoma,NS	c.990C>T	p.P330=	11:32400005-32400005	15
38	COSM111523859	WT1	skin,scalp,malignant melanoma,NS	c.855G>A	p.L285=	11:32427973-32427973	15
39	COSM149724575	WT1	skin,neck,malignant melanoma,NS	c.1373G>A	p.R458Q	11:32392031-32392031	15
40	COSM111534369	WT1	skin,scalp,malignant melanoma,NS	c.1397G>A	p.W466*	11:32389155-32389155	15
41	COSM148573419	WT1	skin,scalp,malignant melanoma,NS	c.1483G>A	p.E495K	11:32389120-32389120	15
42	COSM113486484	WT1	skin,scalp,malignant melanoma,NS	c.742G>A	p.D248N	11:32428524-32428524	15
43	COSM100765008	WT1	skin,scalp,malignant melanoma,NS	c.219G>A	p.L73=	11:32427973-32427973	15
44	COSM91378277	WT1	skin,scalp,malignant melanoma,NS	c.1457G>A	p.W486*	11:32389155-32389155	15
45	COSM148575284	WT1	skin,neck,malignant melanoma,NS	c.1373G>A	p.R458Q	11:32392031-32392031	15
46	COSM130514531	WT1	skin,scalp,malignant melanoma,NS	c.770G>A	p.W257*	11:32389155-32389155	15
47	COSM100776282	WT1	skin,scalp,malignant melanoma,NS	c.405C>T	p.P135=	11:32400005-32400005	15
48	COSM113480145	WT1	skin,scalp,malignant melanoma,NS	c.1041C>T	p.P347=	11:32400005-32400005	15
49	COSM130505084	WT1	skin,scalp,malignant melanoma,NS	c.337G>A	p.D113N	11:32400022-32400022	15
50	COSM148586611	WT1	skin,scalp,malignant melanoma,NS	c.1041C>T	p.P347=	11:32400005-32400005	15

Sources

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Sources

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 160)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁵ Show member pathways GPCR downstream signaling ⁶⁵ Signal Transduction ⁶⁵	14.32	TP53 PTEN NRAS MC1R MAP2K1 KIT
2	Apoptotic Pathways in Synovial Fibroblasts ⁶³ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶³ Cellular Apoptosis Pathway ⁶³ DHA Signaling ⁶³ eIF2 Pathway ⁶³ ERK5 Signaling ⁶³ Glioma Invasiveness ⁶³ Mitochondrial Apoptosis ⁶³ Nuclear Receptor Activation by Vitamin-A ⁶³ p53 Mediated Apoptosis ⁶³ PPAR Pathway ⁶³ Rac1 Pathway ⁶³ Rap1 Pathway ⁶³ Telomerase Components in Cell Signaling ⁶³	13.98	TP53 PTEN NRAS MAP2K1 KIT HRAS
3	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.95	TP53 PTEN NRAS MAP2K1 KIT HRAS
4	GPCR Pathway ⁶³ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶³ Estrogen Pathway ⁶³ NFAT in Immune Response ⁶³ P2Y Receptor Signaling ⁶³ Pancreatic Adenocarcinoma ⁶³ Paxillin Interactions ⁶³ Ras Pathway ⁶³	13.87	TP53 NRAS MAP2K1 KIT HRAS GNA11
5	PEDF Induced Signaling ⁶³ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶³ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶³ Glucocorticoid Receptor Signaling ⁶³ IL-6 Pathway ⁶³ MIF Mediated Glucocorticoid Regulation ⁶³ MIF Regulation of Innate Immune Cells ⁶³ NFAT Signaling and Lymphocyte Interactions ⁶³ PGC1Alpha Pathway ⁶³ RAR-Gamma-RXR-Alpha Degradation ⁶³ STAT3 Pathway ⁶³	13.81	TP53 NRAS MAP2K1 KIT HRAS GNA11
6	Activation of cAMP-Dependent PKA ⁶³ Show member pathways Activation of PKA through GPCR ⁶³ cAMP Pathway ⁶³ PKA Signaling ⁶³	13.71	NRAS MAP2K1 KIT HRAS GNA11 ERBB2
7	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.69	TP53 NRAS MAP2K1 KIT HRAS GNA11
8	Developmental Biology ⁶⁵ Show member pathways Axon guidance ⁶⁵	13.65	NRAS MAP2K1 KIT HRAS ERBB2 CTNNB1
9	Pathways of neurodegeneration - multiple diseases ³⁶ Show member pathways Alzheimer disease ³⁶ Amyotrophic lateral sclerosis ³⁶ Huntington disease ³⁶	13.59	TP53 NRAS MAP2K1 HRAS GNAQ CTNNB1
10	Integrin Pathway ⁶³ Show member pathways FAK1 Signaling ⁶³ GnRH Signaling ⁶³ Inhibition of Angiogenesis by TSP1 ⁶³ Transendothelial Migration of Leukocytes ⁶³ UPA-UPAR Pathway ⁶³	13.57	PTEN NRAS MAP2K1 HRAS GNA11 FBN1
11	Akt Signaling ⁶³ Show member pathways p38 Signaling ⁶³ Tec Kinases Signaling ⁶³	13.55	TP53 PTEN NRAS KIT HRAS GNA11
12	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.51	TP53 NRAS MAP2K1 KIT HRAS ERBB2
13	CREB Pathway ⁶³ Show member pathways Activation of PKC through GPCR ⁶³ Intracellular Calcium Signaling ⁶³ IP3 Pathway ⁶³	13.48	PTEN NRAS MAP2K1 KIT HRAS GNA11
14	Nanog in Mammalian ESC Pluripotency ⁶³ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶³ eNOS Signaling ⁶³ GSK3 Signaling ⁶³	13.44	NRAS MAP2K1 KIT HRAS ERBB2 CTNNB1
15	PAK Pathway ⁶³ Show member pathways Antioxidant Action of Vitamin-C ⁶³ Epithelial Adherens Junctions ⁶³	13.43	PTEN NRAS KIT HRAS ERBB2 CTNNB1
16	IL-2 Pathway ⁶³ Show member pathways ErbB Family Pathway ⁶³ ErbB2-ErbB3 Heterodimers ⁶³ ErbB4 Pathway ⁶³ Growth Hormone Signaling ⁶³ HMGB1 Pathway ⁶³ IL-4 Pathway ⁶³ LPS Stimulated MAPK Signaling ⁶³ PACAP Signaling ⁶³ PI3K Signaling in B-Lymphocyte ⁶³ Prolactin Signaling ⁶³ Thrombopoietin Pathway ⁶³ TREM1 Pathway ⁶³ UVC-Induced MAPK Signaling ⁶³	13.4	TP53 PTEN NRAS MAP2K1 HRAS GNAQ
17	TNFR1 Pathway ⁶³ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²³ Apoptosis through Death Receptors ⁶³ Apoptotic Pathways Triggered By HIV1 ⁶³ Death Receptor Signaling ⁶⁶ DR3 Signaling ⁶³ Fas Signaling ⁶³ GITR Pathway ⁶³ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁵ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶³ TNF Signaling ⁶⁶ TRAIL Pathway ⁶³ TWEAK Pathway ⁶³	13.26	TP53 PTEN NRAS MAP2K1 HRAS GNAQ
18	Phospholipase-C Pathway ⁶³ Show member pathways PTEN Pathway ⁶³	13.24	TP53 PTEN NRAS MAP2K1 KIT HRAS
19	Toll-like Receptor Signaling Pathway ³⁶ ¹ Show member pathways Chagas disease ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ Regulation of toll-like receptor signaling pathway ¹	13.23	TP53 NRAS MAP2K1 HRAS GNAQ GNA11
20	G-Beta Gamma Signaling ⁶³ Show member pathways CRHR Pathway ⁶³ GHRH Signaling ⁶³ Hedgehog Signaling in Mammals ⁶³ Relaxin Pathway ⁶³ Signaling in Gap Junctions ⁶³	13.22	NRAS MAP2K1 HRAS GNA11 CTNNB1 CDKN2A
21	p70S6K Signaling ⁶³ Show member pathways mTOR Pathway ⁶³ Renin-Angiotensin Pathway ⁶³	13.18	NRAS MAP2K1 KIT HRAS GNA11 AKT1
22	fMLP Pathway ⁶³ Show member pathways Alpha-Adrenergic Signaling ⁶³ CCR3 Pathway in Eosinophils ⁶³ CXCR4 Pathway ⁶³ Huntington's Disease Pathway ⁶³ Internalin Pathway ⁶³ Signal transduction Activation of PKC via G-Protein coupled receptor ²³ VEGF and S-1P Signaling ⁶³	13.18	TP53 NRAS MAP2K1 HRAS GNA11 CTNNB1
23	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	13.14	TP53 PTEN NRAS MAP2K1 KIT HRAS
24	Sertoli-Sertoli Cell Junction Dynamics ⁶³ Show member pathways Epithelial Tight Junctions ⁶³ Germ Cell-Sertoli Cell Junction Dynamics ⁶³	13.12	PTEN NRAS MAP2K1 HRAS CTNNB1 CDK4
25	Focal Adhesion ³⁶ ¹ Show member pathways HGF Pathway ⁶³ Integrin-mediated Cell Adhesion ¹	13.09	PTEN NRAS MAP2K1 HRAS ERBB2 CTNNB1
26	Regulation of lipid metabolism Insulin signaling-generic cascades ²³ Show member pathways acetyl-CoA biosynthesis from citrate ¹ Butyrate-induced histone acetylation ¹ Cell adhesion PLAU signaling ²³ Class IB PI3K non-lipid kinase events ¹ Development CNTF receptor signaling ²³ Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²³ ErbB2/ErbB3 signaling events ¹ Glucose Homeostasis ¹ Insulin signaling pathway ³⁶ IRS activation ⁶⁵ Signal attenuation ⁶⁵ Transcription Receptor-mediated HIF regulation ²³ Translation Regulation of EIF2 activity ²³ Translation Regulation of EIF4F activity ²³ Translation Insulin regulation of translation ²³	13.08	PTEN NRAS MAP2K1 HRAS ERBB2 BRAF
27	CCR5 Pathway in Macrophages ⁶³ Show member pathways Androgen Signaling ⁶³ Chemokine Signaling ⁶³ Chemokine signaling pathway ³⁶	13.07	NRAS MAP2K1 HRAS GNAQ GNA11 BRAF
28	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	13.07	TP53 NRAS MAP2K1 HRAS GNAQ GNA11
29	NFAT and Cardiac Hypertrophy ⁶³ Show member pathways IGF1R Signaling ⁶³ Signaling Involved in Cardiac Hypertrophy ⁶³	13.06	PTEN NRAS MAP2K1 HRAS GNA11 ERBB2
30	Development Angiotensin activation of ERK ²³ Show member pathways Cell adhesion Integrin inside-out signaling ²³ Development ACM2 and ACM4 activation of ERK ²³ Development Angiotensin signaling via PYK2 ²³ Development EDNRB signaling ²³ Development EPO-induced MAPK pathway ²³ Development G-Proteins mediated regulation MARK-ERK signaling ²³ Signal transduction IP3 signaling ²³	13.03	NRAS MAP2K1 KIT HRAS GNAQ GNA11
31	Beta-Adrenergic Signaling ⁶³ Show member pathways CDK5 Pathway ⁶³ Erythropoietin Pathway ⁶³ Insulin Receptor Pathway ⁶³	13	NRAS MAP2K1 HRAS GNA11 CTNNB1 BRAF
32	Aldosterone synthesis and secretion ³⁶ Show member pathways Ca2+ activated K+ channels ⁶⁵ Cortisol synthesis and secretion ³⁶ Cushing syndrome ³⁶ Insulin secretion ³⁶ Melanogenesis ³⁶ Thyroid hormone synthesis ³⁶	12.98	NRAS MITF MC1R MAP2K1 KIT HRAS
33	MAPK signaling pathway ³⁶ ¹	12.95	TP53 NRAS MAP2K1 KIT HRAS ERBB2
34	Circadian entrainment ³⁶ Show member pathways Cholinergic synapse ³⁶ Dopaminergic synapse ³⁶ Glutamatergic synapse ³⁶ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁴	12.94	NRAS MAP2K1 HRAS GNAQ GNA11 AKT1
35	Downstream signaling events of B Cell Receptor (BCR) ⁶⁵ Show member pathways Activation of RAS in B cells ⁶⁵ Signaling by the B Cell Receptor (BCR) ⁶⁵	12.92	TP53 PTEN NRAS KIT HRAS ERBB2
36	Ras signaling pathway ³⁶ Show member pathways Rap1 signaling pathway ³⁶	12.92	NRAS MAP2K1 KIT HRAS GNAQ CTNNB1
37	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁴ Show member pathways Adipokines and Insulin Signaling Pathways ⁶⁴ Development Thrombopoietin-regulated cell processes ²³ IL-15 Signaling Pathways ⁶⁴ IL-2 Signaling Pathways ⁶⁴ IL-21 Signaling Pathways ⁶⁴ IL-4 Signaling Pathways ⁶⁴ IL-7 Signaling Pathways ⁶⁴ IL-9 Pathway ⁶³ IL-9 Signaling Pathways ⁶⁴ Immune response IL-9 signaling pathway ²³	12.89	PTEN MAP2K1 HRAS BRAF AKT1
38	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.89	TP53 PTEN NRAS MAP2K1 KIT HRAS
39	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁶ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²³ Apoptosis Signaling Pathways ⁶⁴	12.88	TP53 NRAS MAP2K1 HRAS CDKN2A AKT1
40	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁵ MET activates STAT3 ⁶⁵ Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.87	TP53 PTEN NRAS MAP2K1 HRAS ERBB2
41	Relaxin signaling pathway ³⁶ Show member pathways Estrogen signaling pathway ³⁶ Growth hormone synthesis, secretion and action ³⁶ Relaxin receptors ⁶⁵	12.85	NRAS MAP2K1 HRAS GNAQ GNA11 AKT1
42	4-1BB Pathway ⁶³ Show member pathways CD27 Pathway ⁶³ CD40 Signaling ⁶³ CMV and MAPK Pathways ⁶³ NF-KappaB Activation by EBV ⁶³ NF-kappaB Activation by Viruses ⁶³ PKR Pathway ⁶³ SUMO Pathway ⁶³ TNFR2 Pathway ⁶³	12.85	TP53 NRAS MAP2K1 HRAS BRAF AKT1
43	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁶ Inflammatory mediator regulation of TRP channels ³⁶	12.85	NRAS MAP2K1 HRAS GNAQ GNA11 CTNNB1
44	G-AlphaQ Signaling ⁶³ Show member pathways G-AlphaI Signaling ⁶³ Thrombin Signaling ⁶³	12.84	NRAS MAP2K1 HRAS GNA11 BRAF AKT1
45	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.82	TP53 PTEN NRAS MAP2K1 HRAS ERBB2
46	T cell receptor signaling pathway ³⁶ Show member pathways PD-L1 expression and PD-1 checkpoint pathway in cancer ³⁶ T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.79	PTEN NRAS MAP2K1 HRAS CDK4 AKT1
47	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.77	TP53 NRAS HRAS ERBB2 CTNNB1 AKT1
48	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.75	TP53 PTEN NRAS MITF MAP2K1 HRAS
49	MicroRNAs in cancer ³⁶	12.74	TP53 PTEN NRAS MAP2K1 HRAS ERBB2
50	Immune response Fc epsilon RI pathway ²³ Show member pathways Fc epsilon RI signaling pathway ³⁶ Fc-epsilon receptor I signaling in mast cells ¹ Immune response BCR pathway ²³ VEGF signaling pathway ³⁶	12.73	PTEN NRAS MAP2K1 HRAS AKT1

Sources

GO Terms for Skin Melanoma

Cellular components related to Skin Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	9.5	TP53 PTEN MITF MC1R MAP2K1 KIT
2	protein-containing complex	GO:0032991	9.43	TP53 MITF CTNNB1 CDKN2A CDK4 AKT1

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 43)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.21	TP53 MITF MC1R HRAS CTNNB1 CDKN2A
2	positive regulation of transcription, DNA-templated	GO:0045893	10.12	TP53 MITF MAP2K1 CTNNB1 CDKN2A AKT1
3	protein phosphorylation	GO:0006468	10.09	MAP2K1 KIT ERBB2 CDK4 BRAF AKT1
4	intracellular signal transduction	GO:0035556	10.07	MC1R KIT ERBB2 BRAF AKT1
5	negative regulation of apoptotic process	GO:0043066	10.03	TP53 PTEN MITF CTNNB1 BRAF AKT1
6	phosphorylation	GO:0016310	10.02	MAP2K1 KIT ERBB2 CDKN2A CDK4 BRAF
7	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.98	PTEN MAP2K1 HRAS BRAF
8	negative regulation of gene expression	GO:0010629	9.98	TP53 MAP2K1 HRAS CTNNB1 AKT1
9	negative regulation of cell proliferation	GO:0008285	9.97	TP53 PTEN MAP2K1 HRAS CTNNB1 CDKN2A
10	protein stabilization	GO:0050821	9.96	TP53 PTEN GNAQ CDKN2A
11	positive regulation of cell proliferation	GO:0008284	9.95	PTEN KIT HRAS ERBB2 CTNNB1 CDK4
12	signal transduction	GO:0007165	9.93	NRAS MC1R MAP2K1 KIT HRAS GNAQ
13	positive regulation of apoptotic process	GO:0043065	9.91	TP53 PTEN CTNNB1 CDKN2A CDK4 AKT1
14	peptidyl-tyrosine phosphorylation	GO:0018108	9.89	MAP2K1 KIT ERBB2 BRAF
15	cell cycle arrest	GO:0007050	9.88	TP53 MAP2K1 HRAS CDKN2A
16	cellular response to growth factor stimulus	GO:0071363	9.85	ERBB2 CTNNB1 AKT1
17	positive regulation of MAPK cascade	GO:0043410	9.85	KIT HRAS ERBB2 CTNNB1
18	MAPK cascade	GO:0000165	9.85	NRAS MAP2K1 KIT HRAS ERBB2 BRAF
19	negative regulation of G1/S transition of mitotic cell cycle	GO:2000134	9.84	PTEN CDKN2A CDK4
20	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.84	PTEN KIT CTNNB1 AKT1
21	positive regulation of MAP kinase activity	GO:0043406	9.82	KIT HRAS ERBB2
22	thymus development	GO:0048538	9.8	MAP2K1 CTNNB1 BRAF
23	cellular response to nerve growth factor stimulus	GO:1990090	9.78	PTEN BRAF AKT1
24	phosphatidylinositol 3-kinase signaling	GO:0014065	9.77	PTEN ERBB2 AKT1
25	Ras protein signal transduction	GO:0007265	9.76	TP53 NRAS HRAS CDKN2A
26	pigmentation	GO:0043473	9.74	MITF MC1R KIT
27	regulation of cell proliferation	GO:0042127	9.73	TP53 MITF KIT CTNNB1 CDK4 BRAF
28	developmental pigmentation	GO:0048066	9.69	KIT GNA11
29	negative regulation of cell size	GO:0045792	9.69	PTEN AKT1
30	cellular senescence	GO:0090398	9.69	MAP2K1 HRAS CDKN2A
31	cellular response to insulin-like growth factor stimulus	GO:1990314	9.68	PTEN FBN1
32	somatic stem cell division	GO:0048103	9.68	KIT CDKN2A
33	phototransduction, visible light	GO:0007603	9.68	GNAQ GNA11
34	positive regulation of DNA-templated transcription, initiation	GO:2000144	9.65	MITF CTNNB1
35	entrainment of circadian clock	GO:0009649	9.65	GNAQ GNA11
36	trachea formation	GO:0060440	9.64	MAP2K1 CTNNB1
37	myeloid progenitor cell differentiation	GO:0002318	9.63	KIT BRAF
38	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.63	ERBB2 CDKN2A
39	cellular response to decreased oxygen levels	GO:0036294	9.61	PTEN AKT1
40	canonical Wnt signaling pathway involved in negative regulation of apoptotic process	GO:0044336	9.52	MITF CTNNB1
41	regulation of axon regeneration	GO:0048679	9.5	PTEN MAP2K1 BRAF
42	heart development	GO:0007507	9.5	TP53 PTEN MAP2K1 GNA11 FBN1 ERBB2
43	positive regulation of gene expression	GO:0010628	9.36	TP53 PTEN MITF MAP2K1 KIT HRAS

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	9.88	TP53 PTEN CTNNB1 CDKN2A AKT1
2	protein-containing complex binding	GO:0044877	9.8	NRAS HRAS FBN1 CDK4 BRAF
3	protein C-terminus binding	GO:0008022	9.73	MAP2K1 HRAS ERBB2 CTNNB1
4	protein kinase activity	GO:0004672	9.63	MAP2K1 KIT ERBB2 CDK4 BRAF AKT1
5	protein tyrosine kinase activity	GO:0004713	9.56	MAP2K1 KIT ERBB2 BRAF
6	disordered domain specific binding	GO:0097718	9.5	TP53 CTNNB1 CDKN2A
7	kinase activity	GO:0016301	9.5	MAP2K1 KIT ERBB2 CDKN2A CDK4 BRAF
8	MDM2/MDM4 family protein binding	GO:0097371	9.46	TP53 CDKN2A
9	type 2A serotonin receptor binding	GO:0031826	9.37	GNAQ GNA11
10	nucleotide binding	GO:0000166	9.32	NRAS MAP2K1 KIT HRAS GNAQ GNA11

Sources

Sources for Skin Melanoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Skin Melanoma

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Classifications:

External Ids:

Summaries for Skin Melanoma

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Skin Melanoma:

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:

GenomeRNAi Phenotypes related to Skin Melanoma according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Skin Melanoma:

Drugs & Therapeutics for Skin Melanoma

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 71 / NDF-RT 51 :

Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

Publications for Skin Melanoma

Articles related to Skin Melanoma:

Genes for Skin Melanoma

Genes related to Skin Melanoma (10 elite genes):

Variations for Skin Melanoma

ClinVar genetic disease variations for Skin Melanoma:

Cosmic variations for Skin Melanoma:

Expression for Skin Melanoma

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

GO Terms for Skin Melanoma

Cellular components related to Skin Melanoma according to GeneCards Suite gene sharing:

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

Sources for Skin Melanoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵¹ :